Rajiv Sinha, Nirav Agrawal, Yuanxin Xue, Rahul Chanchlani, Subal Pradhan, Rupesh Raina, Stephen D Marks
6 min
Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen on B cells, has transitioned from its origins in oncology to become a significant therapeutic tool in pediatric nephrology. This review examines its mechanism, clinical applications, and the practical considerations for pediatricians managing children on this therapy.
Rituximab induces B cell depletion through three primary pathways: antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis in abnormal B cells. Beyond B cell depletion, the drug appears to influence T cell differentiation and may have direct stabilizing effects on podocytes, though the clinical significance of the latter is debated. By reducing B cell populations, rituximab effectively lowers the production of autoreactive antibodies, making it particularly useful in autoimmune-mediated renal diseases.
While generally well-tolerated, rituximab carries risks of infusion reactions and increased susceptibility to infections due to prolonged B cell suppression. Vaccination strategies must be carefully managed, as the drug blunts both humoral and cellular immune responses. Clinicians should prioritize administering non-live vaccines at least one week before infusion and avoid live vaccines for several months post-treatment. Long-term monitoring of immunoglobulin levels and B cell recovery is essential to guide future dosing and minimize adverse outcomes.
Rituximab is a chimeric monoclonal antibody capable of depleting B cell populations by targeting the CD20 antigen expressed on the cell surface. Its use in oncology, initially in B cell lymphoma and post-transplant lymphoproliferative disorders, predates its current utility in various fields of medicine wherein it has become one of the safest and most effective antibody-based therapies. It was subsequently found to be effective for rheumatological conditions such as rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis. Over the past decade, rituximab has generated a lot of interest in nephrology and has become an emerging or accepted therapy for multiple renal conditions, including systemic lupus erythematosus, lupus nephritis, vasculitis, nephrotic syndrome and in different scenarios before and after kidney transplantation. This review outlines its current use in paediatric nephrology practice, focusing on the knowledge required for general paediatricians who may be caring for children prescribed this medication and reviewing them on a shared care basis.
Sam: What about the practical limitations — the pharmacokinetics side?
Alex: That's where the evidence gets thinner. The core challenge is that we've largely borrowed dosing protocols from oncology, where the target is tumor burden and you're willing to accept aggressive depletion. In nephrotic syndrome, that calculus is different. The patients are children, the disease is chronic and relapsing, and the goal is sustained remission rather than a single ablative course.
Sam: So the oncology-derived dosing might be overkill?
Alex: Possibly, yes. And the timing question is equally unresolved. Delayed reconstitution of memory B cells appears to be a marker for durable response — the longer B cells stay suppressed, the longer the remission tends to hold. But that same window of depletion leaves patients vulnerable to encapsulated bacterial infections. So you're managing a trade-off between efficacy and infectious risk that current protocols don't resolve cleanly.
Sam: Is there a monitoring strategy that helps navigate that?
Alex: The paper discusses CD19 count as a surrogate for B-cell reconstitution — you can track when the population starts to recover and use that to guide re-dosing decisions. But the thresholds aren't well-validated in pediatric populations. Most of the evidence here is observational, and the heterogeneity across studies in terms of dosing, patient selection, and outcome definitions makes it hard to extract firm guidance.
Sam: That's a significant gap. What about the safety signal more broadly?
Alex: The acute infusion reactions are manageable with premedication — that's fairly well-characterized. The longer-term concern is hypogammaglobulinemia, which can develop after repeated courses. In a child who's going to need multiple rounds over years, cumulative immunoglobulin depletion is a real consideration. The paper flags this but acknowledges the longitudinal data in pediatric nephrotic syndrome specifically are limited.
Sam: So where does that leave the overall evidentiary picture?
Alex: The mechanism is well-supported. The clinical signal — particularly in steroid-dependent and frequently relapsing nephrotic syndrome — is consistent across multiple cohort studies and a handful of randomized trials. Rituximab does reduce relapse rates and allows steroid tapering in a meaningful proportion of patients. What the evidence doesn't yet support is confident guidance on optimal dosing, retreatment intervals, or long-term safety in pediatric populations specifically. The paper is essentially making the case that the benefit-risk ratio is favorable enough to justify use, while being candid that the field still needs prospective data with standardized protocols.
Sam: So the clinical case is reasonable, but the implementation is still running ahead of the evidence base.
Alex: That's a fair characterization. And it's worth noting that the off-label status in many jurisdictions compounds this — it shapes what data gets collected, how trials get funded, and whether families have access at all. The evidentiary gaps and the regulatory gaps are reinforcing each other.
Sam: That's a genuinely difficult position for a clinician to be in — enough signal to act, not enough to act with confidence.
Alex: It is. And I think that's the honest takeaway from this paper. It's not making a triumphalist case for Rituximab. It's making a careful argument that for a child facing years of steroid toxicity, the current evidence supports a trial of B-cell depletion — while being explicit about what we still don't know. That kind of epistemic honesty is actually useful for a practicing clinician trying to have an informed conversation with a family.
Sam: Thanks for walking through that. There's clearly more work to be done, but the mechanistic logic and the emerging clinical evidence make this a space worth watching closely.
Alex: Agreed. Thanks for listening to ResearchPod.